<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/5609975#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Catalysis rdf:ID="Catalysis12">
 <bp:controlled rdf:resource="#BiochemicalReaction12" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis11">
 <bp:controlled rdf:resource="#BiochemicalReaction11" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis14">
 <bp:controlled rdf:resource="#BiochemicalReaction14" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis13">
 <bp:controlled rdf:resource="#BiochemicalReaction13" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis15">
 <bp:controlled rdf:resource="#BiochemicalReaction15" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DHDDS does not elongate E,E-FPP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPI does not  isomerize Fru6P to Man6P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNE does not phosphorylate ManNAc to ManNAc-6-P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALT does not transfer UMP to Gal1P</bp:displayName>
</bp:BiochemicalReaction>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PMM2 does not isomerise Man6P to Man1P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM1 does not transfer mannose to DOLP to form DOLPman</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM2 does not transfer mannose to DOLP to form DOLPman</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SRD5A3 does not reduce pPNOL to DCHOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DOLK does not phosphorylate DCHOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction1" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction3" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
 <bp:stepProcess rdf:resource="#Catalysis15" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction2" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction5" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction4" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction7" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction6" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:pathwayComponent rdf:resource="#Pathway14" />
 <bp:pathwayComponent rdf:resource="#Pathway15" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with glycosylation precursor biosynthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylation diseases associated with the enzymes that mediate the biosynthesis of glycosylation precursors are curated in this section (Jaeken    Matthijs 2007, Freeze et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction9" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
 <bp:stepProcess rdf:resource="#Catalysis12" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PMM2 causes PMM2-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphomannomutase 2 (PMM2) normally catalyses the isomerisation of mannose 6-phosphate (Man6P) to mannose 1-phosphate (Man1P) in the cytosol of cells. Man1P is a precursor in the synthesis of GDP-mannose and dolichol-phosphate-mannose, required for critical mannosyl transfer reactions in the N-glycosylation of proteins. Mutations in the PMM2 gene are one of the causes of Jaeken syndrome, a congenital disorder of glycosylation type 1a (PMM2-CDG, previously CDG-1a) (Matthijs et al. 1997). PMM2-CDG was first described in Belgian identical twin sisters, characterized by psychomotor retardation and multiple serum glycoprotein abnormalities. Serum and CSF transferrin were found to be deficient in sialic acid (Jaeken et al. 1984). PMM2-CDG is the most common CDG disease subtype.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction8" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM2 causes DPM2-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM2 can cause congenital disorder of glycosylation 1u (DPM2-CDG, CDG1u; MIM:615042), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Barone et al. 2012). CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
 <bp:stepProcess rdf:resource="#Catalysis11" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM1 causes DPM1-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM1 can cause congenital disorder of glycosylation 1e (DPM1-CDG, CDG-1e; MIM:608799), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Kim et al. 2000, Imbach et al. 2000, Garcia-Silva et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
 <bp:stepProcess rdf:resource="#Catalysis14" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#Pathway15" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
 <bp:stepProcess rdf:resource="#Catalysis13" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#Pathway14" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALT can cause GALCT</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Galactose-1-phosphate uridylyltransferase (GALT) is one of the enzymes involved in galactose metabolism in the Leloir pathway. GALT catalyses the transfer of uridine monophosphate (UMP) from UDP-glucose (UDP-Glc) to galactose-1-phosphate (Gal1P) to form UDP-galactose (UDP-Gal) and glucose 1-phosphate. Defects in GALT can cause Galactosemia (GALCT; MIM:230400), an autosomal recessive disorder of galactose metabolism presenting in neonatals that causes jaundice, cataracts and mental retardation (Bosch 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DOLK causes DOLK-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichol kinase (DOLK, TMEM15) normally mediates the phosphorylation of dolichol (DCHOL) to form dolichyl phosphate (DOLP) in the ER membrane (Fernandez et al. 2002). DOLP is an important substrate in the synthesis of N- and O-glycosylated proteins and GPI anchors. Defects in DOLK cause congenital disorder of glycosylation type 1m (DOLK-CDG, CDG1m, also known as dolichol kinase deficiency; MIM:610768), a severe mutisystem disorder characterised by under-glycosylated serum glycoproteins. This disorder has a very severe phenotype and death can occur in early life (Kranz et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SRD5A3 causes SRD5A3-CDG, KHRZ</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polyprenol reductase (SRD5A3), resident on the endoplasmic reticulum membrane, normally mediates the reduction of the alpha-isoprene unit of polyprenol (pPNOL) to form dolichol (DCHOL) in a NADPH-dependent manner (Cantagrel et al. 2010). DCHOLs are substrates required for the synthesis of the lipid-linked oligosaccharide (LLO) precursor used for N-glycosylation. Defects in SRD5A3 cause congenital disorder of glycosylation 1q (SRD5A3-CDG, CDG1q; MIM:612379), a neurodevelopmental disorder characterised by under-glycosylated serum glycoproteins resulting in nervous system development, psychomotor retardation, hypotonia, coagulation disorders and immunodeficiency (Cantagrel et al. 2010, Kasapkara et al. 2012). Defects in SRD5A3 can also cause Kahrizi syndrome (KHRZ; MIM:612713), a neurodevelopmental disorder characterised by mental retardation, cataracts, holes in eye structures, pathological curvature of the spine, and coarse facial features (Kahrizi et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPI causes MPI-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mannose 6-phosphate isomerase (MPI) normally isomerises fructose 6-phosphate (Fru6P) to mannose 6-phosphate (Man6P) in the cytosol. Man6P is a precursor in the synthesis of GDP-mannose and dolichol-phosphate-mannose, required for mannosyl transfer reactions in the N-glycosylation of proteins. Defects in MPI cause congenital disorder of glycosylation 1b (MPI-CDG, previously known as CDG1b,; MIM:602579), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Schollen et al. 2000). Unlike PMM2-CDG (CDG1a), there is no neurological involvement with MPI-CDG. Instead, patients present predominantly with diarrhoea, failure to thrive and protein-losing enteropathy (Pelletier et al. 1986). MPI-CDG is one of two CDGs that can be treated with oral mannose supplementation, but can be fatal if left untreated (Marquardt    Denecke 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DHDDS causes RP59</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The ER membrane-associated enzyme dehydrodolichyl diphosphate synthase (DHDDS) (Endo et al. 2003) normally mediates the sequential head-to-tail cis addition of multiple isopentyl pyrophosphate (IPP) molecules to farnesyl pyrophosphate (E,E-FPP) to produce polyprenol pyrophosphate (pPPP) (Shridas et al. 2003). Dolichol in humans contain homologues ranging from 17-23 isoprene units, the most common homologues contain 19 or 20 isoprene units (Freeman et al. 1980). Dolichol is an important substrate in the N-glycosylation of proteins, including rhodopsin.  Defects in DHDDS cause retinitis pigmentosa 59 (RP59; MIM:613861), a pigment retinopathy, characterised by retinal pigment deposits (visible on fundus examination) and primary loss of rod photoreceptors followed by secondary loss of cone photoreceptors. Sufferers typically have night vision blindness and loss of mid to peripheral vision. As the condition progresses, they lose far peripheral vision and eventually central vision (Zuchner et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALE does not epimerise UDP-Gal to UDP-Glc</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALK1 does not phosphorylate Gal</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNE does not hydrolyse UDP-GlcNAc</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
 <bp:stepProcess rdf:resource="#Catalysis9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#Catalysis10" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GFPT1 does not transfer an amino group from L-Gln to F6P to form GlcN6P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PGM1 does not isomerise G6P to G1P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM3 does not transfer mannose to DOLP to form DOLPman</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
 <bp:stepProcess rdf:resource="#Catalysis6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#Catalysis5" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
 <bp:stepProcess rdf:resource="#Catalysis8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
 <bp:stepProcess rdf:resource="#Catalysis7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#Catalysis4" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#Catalysis3" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#Catalysis2" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Catalysis1" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction10" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNE causes sialuria, NK and IBM2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sialuria (MIM:269921) is caused by a metabolic defect where the UDP?N?acetylglucosamine 2?epimerase, N?acetylmannosamine kinase (GNE) gene lacks feedback inhibition resulting in constitutive overproduction of free sialic acid (Neu5Ac) (Montreuil et al. 1968, Fontaine et al. 1968). Sialuria is characterised by a large cytoplasmic accumulation and urinary excretion of Neu5Ac (Kamerling et al. 1979). Sialurias differ from sialidoses, in which there is storage and excretion of &apos;bound&apos; Neu5Ac. Defects in GNE also cause Nonaka myopathy (NK; MIM:605820), an early adult-onset disorder characterised by muscle weakness and wasting of distal muscles, especially the anterior tibial muscles (Nonaka et al. 1981, Asaka et al. 2001). Defects in GNE also cause inclusion body myopathy 2 (IBM2; MIM:600737), an autosomal recessive disorder with a similar phenotype to Nonaka myopathy (NK). IBM2 is an adult-onset, proximal and distal muscle weakness and wasting disorder. Muscle biospsy reveals from sufferers shows a rimmed vacuole myopathy and the degenerating muscle fibers contained abnormal amounts of beta-amyloid protein such as that found in neurodegenerative diorders. However, there is no neurological symptoms in these patients (Argov    Yarom 1984).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALK1 causes GALCT2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic galactokinase (GALK1) catalyses the first committed step in the Leloir pathway of galactose metabolism. GALK1 catalyses the phosphorylation of D-galactose (Gal) to form D-galactose 1-phosphate (Gal1P). Defects in GALK1 can cause type II galactosemia (GALCT2; MIM:230200), an autosomal recessive deficiency characterised by congenital cataracts during infancy and presenile cataracts in the adult population. Galactitol accumulation in the lens is the cause of these cataracts (Bosch et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALE causes EDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic UDP-galactose 4&apos;-epimerase (GALE) catalyses the reversible interconversion of UDP-D-galactose (UDP-Gal) and UDP-glucose (UDP-Glc), the third reacton in the Leloir pathway of galactose metabolism. GALE can also catalyse the epimerisation of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The active form of the enzyme is a homodimer with one molecule of bound NAD per monomer (GALE:NAD+ dimer). Defects in GALE can cause Epimerase-deficiency galactosemia (EDG; MIM:230350), or type III galactosemia (diseases of galactose metabolism) whose clinical features include early-onset cataracts, liver damage, deafness and mental retardation. Historically, it was considered that there were two forms of GALE deficidency; a benign (&quot;peripheral&quot;) form where there is no GALE activity in red blood cells and characterised by mild symptoms (Gitzelmann 1972) and a rarer &quot;generalised&quot; form with no detectable GALE activity in all tissues resulting in more severe symptoms (Holton et al. 1981). The disease is now considered to be a continuum (Openo et al. 2006).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM3 causes DPM3-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM3 can cause congenital disorder of glycosylation 1o (DPM3-CDG, CDG1o; MIM:612937), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency (Lefeber et al. 2009).  Four biosynthetic pathways depend on DOLPman; N-glycosylation, O-mannosylation, C-Mannosylation and GPI-anchor biosynthesis. A defect in DPM3 strongly reduces O-mannosylation of alpha-dystroglycan, explaining the clinical phenotype of muscular dystrophy and linking the congenital disorders of glycosylation with the dystroglycanopathies (Lefeber et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway14">
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PGM1 causes PGM1-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphoglucomutases 1 and 2 (PGM1, 2) are involved in the cytosolic biosynthesis of nucleotide sugars needed for glycan biosynthesis, specifically, the isomerisation of glucose-6-phosphate (G6P) into glucose-1-phosphate (G1P). Defects in PGM1 can cause congenital disorder of glycosylation 1t (CDG1t, now known as PGM1-CDG; MIM:614921), a broad spectrum disorder characterised by under-glycosylated serum glycoproteins (Timal et al. 2012, Tegtmeyer et al. 2014). CDGs result in a wide variety of clinical features such as defects in nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway15">
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GFPT1 causes CMSTA1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glucosamine-fructose 6-phosphate aminotransferases 1 and 2 (GFPT1,2) are the first and rate-limiting enzymes in the hexosamine synthesis pathway, and thus formation of hexosamines like N-acetylglucosamine (GlcNAc). These enzymes probably play a role in limiting the availability of substrates for the N- and O-linked glycosylation of proteins. GFPT1 and 2 are required for normal functioning of neuromuscular synaptic transmission. Defects in GFPT1 lead to myasthenia, congenital, with tubular aggregates 1 (CMSTA1; MIM:610542), characterised by altered muscle fibre morphology and impaired neuromuscular junction development. Sufferers of CMSTA1 show a good response to acetylcholinesterase inhibitors (Senderek et al. 2011). The missense mutations observed do not always result in significant reduction in enzyme activity, but biopsies show reduced amounts of GFPT1 protein suggesting increased turnover or defective translation (Senderek et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>
</rdf:RDF>